HLB Life Science Co Ltd
067630
Company Profile
Business description
HLB Life Science Co Ltd and its subsidiaries are engaged in the medicare business, bio development business, medical device business, and drug distribution business. The company is a medical device for in vitro diagnostics.The main business is the Medicare business, which includes foot and manufacturing, quasi-drug component development, and finished product consignment production.
Contact
3-10th Floor, Pangyo Seven Venture Valley 1-danji
15, Pangyo-ro 228 beon-gil
Gyeonggi-do
Seongnam-si
KORT: +82 226276700
Sector
Healthcare
Stock type
Defensive
Industry
Medical Distribution
Fiscal Year End
31 December 2026
Employees
187
Stocks News & Analysis
stocks
Meta earnings: Strong end to 2025 as AI monetization begins to show
Investors please with latest results.
stocks
Why doesn’t the market like the earnings from this US tech giant?
Good quarter with AI demand ramping.
stocks
Our Tesla fair value increases meaningfully
Progress on Robotaxi and Optimus shows real world AI growth.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,164.80 | 78.50 | -0.85% |
| CAC 40 | 8,071.36 | 4.68 | 0.06% |
| DAX 40 | 24,309.46 | 513.33 | -2.07% |
| Dow JONES (US) | 48,972.05 | 43.55 | -0.09% |
| FTSE 100 | 10,171.76 | 17.33 | 0.17% |
| HKSE | 27,407.10 | 419.81 | -1.51% |
| NASDAQ | 23,685.12 | 172.33 | -0.72% |
| Nikkei 225 | 53,322.85 | 35.86 | -0.07% |
| NZX 50 Index | 13,423.18 | 10.31 | 0.08% |
| S&P 500 | 6,939.31 | 38.72 | -0.55% |
| S&P/ASX 200 | 8,869.10 | 54.10 | -0.61% |
| SSE Composite Index | 4,117.95 | 40.04 | -0.96% |